Group 1: Financial Developments - Penumbra's shares surged nearly 12% to around $350 following the announcement of its acquisition by Boston Scientific, which values Penumbra at $374 per share and approximately $14.5 billion in enterprise value [2][5] - Wells Fargo has set a price target of $374 for Penumbra, indicating a 6.47% increase from its current trading price of $351.27, but downgraded the stock to Equal Weight from Overweight [1][5] Group 2: Acquisition Details - Under the acquisition agreement, Penumbra shareholders can choose to receive either $374 in cash or 3.87 shares of Boston Scientific stock for each share they hold, with the total consideration being approximately 73% cash and 27% stock [3][5] - Boston Scientific plans to finance the $11 billion cash portion of the acquisition using cash on hand and new debt, with the transaction expected to close in 2026, pending shareholder approval [3] Group 3: Stock Performance - Penumbra's stock has experienced a significant increase of 12.07%, translating to a rise of $37.85, with today's trading volume at 6,385,647 shares [4] - The stock fluctuated between a low of $345.20 and a high of $352.15, marking its highest point for the year, while the lowest price over the past year was $221.26 [4]